Novartis AG Overview
Company Headquarters: Basel, Switzerland
Founded: 1996
Workforce: ~126,000
Company Working:
Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Strategy
Novartis strategizes to use science-based innovations to improve patient outcomes in order to become a leader in growing areas of healthcare. The company seeks to develop medicines and products that can produce positive results for patients and healthcare providers to improve the cost-effectiveness of high-quality care to patients. By collaborating with new healthcare providers and technology companies, the company intends to develop services and technologies to amplify the benefits of its core products. Its prime focus lies in patented medicine, generic medicine, and eye care segments where it has the innovation power and global scale necessary to compete effectively. Meanwhile, the company aims to expand its presence in the emerging markets of Asia, Africa, and Latin America, where there has been a fast-growing demand for access to high-quality medicines and healthcare.
